Trial Profile
A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Low- and High-dose Range Groups of SPD489 as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 07 Jun 2021
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- 01 Jun 2021 Planned End Date changed from 1 Feb 2014 to 24 Feb 2014.
- 01 Jun 2021 Planned primary completion date changed from 1 Feb 2014 to 24 Feb 2014.
- 06 Sep 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.